Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
18 Maggio 2023 - 3:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May 2023
Commission File Number: 001-39481
PainReform Ltd.
(Translation of registrant’s name into English)
65 Yigal Alon St., Tel Aviv 6744316
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This first two paragraphs of the press release attached as Exhibit 99.1 to this Report on Form 6-K is incorporated by reference into the
Company’s Registration Statement on Form S-8 (Registration No. 333-257968 and 333-265902) and Form F-3 (File No. 333-259318), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
On May 18, 2023, PainReform Ltd. issued a press release entitled “PainReform Announces Positive Pharmacokinetic (PK) Data in First Part
of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery”. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Date: May 18, 2023
|
PAINREFORM LTD.
|
|
|
|
|
|
By:
|
/s/ Ilan Hadar
|
|
|
|
Ilan Hadar
|
|
|
|
Chief Executive Officer
|
|
3
Grafico Azioni PainReform (NASDAQ:PRFX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni PainReform (NASDAQ:PRFX)
Storico
Da Giu 2023 a Giu 2024